1. 康哲药业
  2. 康哲药业
  3. 康哲药业

Business

Innovative Research and Future Development

CMS concentrates on the deployment of global first-in-class or the innovative products with the best efficacy and cost-effectiveness in the same class due to their innovative formulations or drug delivery systems. So far, the Group has invested in the equity of a number of overseas innovative R&D companies from the United Kingdom, France, Switzerland, the United States, etc. and acquired assets or rights of their innovative products in Greater China or Mainland China. In the meantime, the Group has established collaborations with four world’s leading pharmaceutical companies and acquired the product rights of their innovative products in Greater China and Mainland China by licensing-in. The Group has owned nearly twenty innovative products with promising market potential and competitive differentiation advantages at relatively higher innovation levels. The Group’s innovative pipeline covers various therapeutic fields including ophthalmology, dermatology, nervous system, oncology, immune system, digestive system, anti-infection, endocrine system, etc. Among them, five products have been approved by the U.S. FDA; one product is under the marketing approval process of the U.S. FDA; six products are at Phase III clinical stage, and others are at Phase II clinical stage.

More>>

Professional Academic Promotion

The Group has proven experiences in the academic promotion of prescription drugs, market access and government affairs. The Group has established a comprehensive, complete, professional and mature academic promotion system consisting of medicine, marketing, sales, commerce, retail, quality management and supply chain management. Over the past two decades, CMS has established close cooperation with dozens of global leading pharmaceutical companies. With its compliant, efficient and professional academic promotion team, CMS has successfully established professional brand images and achieved good historical sales records for a number of quality products in China, which has been highly recognized from its cooperative partners.

More>>

Pharmaceutical Manufacturing

Some of the Group's imported products are entrusted the manufacture to overseas pharmaceutical manufactures while some domestic products are self-produced. The Group has pharmaceutical manufacturing sites in Hebei and Hunan Province, covering a total area of more than 70,000 square meters. And the Group has the Pharmaceutical Production License and the Pharmaceutical GMP Certificate for various dosage forms such as powder, oral solution, small-volume injections, tablets, hard capsules and so on.

More>>

Products

Partners of Existing Products

CMS has created professional brand image and good sales records for a number of quality branded drugs in China, and received the high recognition from dozens of partners of existing products.

More>>

Innovative Research

CMS concentrates on the deployment of global first-in-class or the innovative products with the best efficacy and cost-effectiveness in the same class due to their innovative preparations or drug delivery systems. Via equity investment or strategic cooperation, the Group has acquired abundant innovative pipeline covering a wide range of therapeutic areas. So far, the Group has owned nearly twenty innovative products with promising market potential and competitive differentiation advantages.

More>>

Investor Relations

Announcements & Circulars

  • 2020-08-04
    Monthly Return of Equity Issuer on Movements in Securities
  • 2020-07-31
    Terms of Reference of the Remuneration Committee
  • 2020-07-31
    Terms of Reference of the Nomination Committee
  • 2020-07-31
    Terms of Reference of the Audit Committee
  • 2020-07-31
    Notice of Board Meeting
  • 2020-07-02
    Monthly Return of Equity Issuer on Movements in Securities
  • More>>

    Financial Reports

  • Annual Report 2019

  • Interim Report 2019

  • Annual Report 2018

  • Interim Report 2018

  • Annual Report 2017

  • Interim Report 2017

  • More>>

    Stock Quotes